Ashton Thomas Private Wealth LLC Makes New $262,000 Investment in IQVIA Holdings Inc. (NYSE:IQV)

Ashton Thomas Private Wealth LLC purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 1,334 shares of the medical research company’s stock, valued at approximately $262,000.

Several other institutional investors also recently modified their holdings of IQV. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA during the 3rd quarter worth approximately $27,000. Synergy Asset Management LLC acquired a new stake in shares of IQVIA during the 4th quarter worth approximately $33,000. Avior Wealth Management LLC grew its position in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the period. Assetmark Inc. grew its position in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after buying an additional 196 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of IQVIA during the 3rd quarter worth approximately $57,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $183.72 on Wednesday. The company’s fifty day simple moving average is $197.36 and its 200-day simple moving average is $211.78. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market cap of $32.39 billion, a PE ratio of 24.50, a P/E/G ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $261.72.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on IQV shares. Robert W. Baird decreased their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Truist Financial restated a “buy” rating and set a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Citigroup decreased their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Finally, Stifel Nicolaus decreased their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.